

EQA round: AIH2/21 - Autoimmune Liver Diseases

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test	Sample	Group		N	Result	N _{rel}
(451) AMA						
A	(1)	Fluorescent methods	>>>	52	Negative	98 %
				1	Positive	1,9 %
	Total per sample: n = 53		Success: 98 %			
B	(1)	Fluorescent methods	>>>	53	Negative	100 %
	Total per sample: n = 53		Success: 100 %			
Total success: 98 %						
(456) AMA-M2						
A	(2)	EIA methods	>>>	12	Negative	19 %
	(5)	Immunoblotting	>>>	50	Negative	81 %
	Total per sample: n = 62		Success: 100 %			
B	(2)	EIA methods	>>>	12	Negative	19 %
	(5)	Immunoblotting	>>>	50	Negative	81 %
	Total per sample: n = 62		Success: 100 %			
Total success: 100 %						
(454) anti-gp210						
A	(2)	EIA methods	>>>	1	Negative	2,2 %
	(5)	Immunoblotting	>>>	44	Negative	98 %
	Total per sample: n = 45		Success: 100 %			
B	(2)	EIA methods	>>>	1	Negative	2,2 %
	(5)	Immunoblotting	>>>	43	Negative	96 %
				1	Inconclusive result (borderline)	2,2 %
	Total per sample: n = 45		Success: 98 %			
Total success: 98 %						
(457) anti-LC-1						
A	(2)	EIA methods	>>>	4	Negative	7,1 %
	(5)	Immunoblotting	>>>	52	Negative	93 %
	Total per sample: n = 56		Success: 100 %			
B	(2)	EIA methods	>>>	4	Negative	7,1 %
	(5)	Immunoblotting	>>>	51	Negative	91 %
				1	Inconclusive result (borderline)	1,8 %
	Total per sample: n = 56		Success: 98 %			
Total success: 98 %						
(452) anti-LKM						
A	(1)	Fluorescent methods	>>>	43	Negative	98 %
				1	Positive	2,3 %
	Total per sample: n = 44		Success: 98 %			
B	(1)	Fluorescent methods	>>>	4	Negative	9,1 %
			>>>	40	Positive	91 %
	Total per sample: n = 44		Success: 91 %			
Total success: 91 %						
(455) anti-LKM1						
A	(2)	EIA methods	>>>	13	Negative	21 %
	(5)	Immunoblotting	>>>	48	Negative	79 %
	Total per sample: n = 61		Success: 100 %			
B	(2)	EIA methods	>>>	1	Negative	1,6 %
			>>>	12	Positive	20 %
	(5)	Immunoblotting	>>>	48	Positive	79 %
	Total per sample: n = 61		Success: 98 %			
Total success: 98 %						
(458) anti-SLA						
A	(1)	Fluorescent methods	>>>	1	Negative	1,7 %
	(2)	EIA methods	>>>	7	Negative	12 %
	(5)	Immunoblotting	>>>	52	Negative	87 %
	Total per sample: n = 60		Success: 100 %			
B	(1)	Fluorescent methods	>>>	1	Negative	1,7 %
	(2)	EIA methods	>>>	7	Negative	12 %
	(5)	Immunoblotting	>>>	47	Negative	78 %
				5	Inconclusive result (borderline)	8,3 %
	Total per sample: n = 60		Success: 92 %			
Total success: 92 %						
(459) anti-sp100						

Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: AIH2/21 - Autoimmune Liver Diseases

Deadline: 22.10.2021

Test			N	Result	N _{rel}
Sample	Group				
A	(1) Fluorescent methods	>>>	1	Negative	2,2 %
	(2) EIA methods	>>>	1	Negative	2,2 %
	(5) Immunoblotting	>>>	44	Negative	96 %
	Total per sample: n = 46		Success: 100 %		
B	(1) Fluorescent methods	>>>	1	Negative	2,2 %
	(2) EIA methods	>>>	1	Negative	2,2 %
	(5) Immunoblotting	>>>	44	Negative	96 %
	Total per sample: n = 46		Success: 100 %		
Total success: 100 %					

(453) SMA					
A	(1) Fluorescent methods	>>>	53	Negative	98 %
	(5) Immunoblotting	>>>	1	Negative	1,9 %
	Total per sample: n = 54		Success: 100 %		
B	(1) Fluorescent methods	>>>	52	Negative	96 %
			1	Positive	1,9 %
	(5) Immunoblotting	>>>	1	Negative	1,9 %
Total per sample: n = 54		Success: 98 %			
Total success: 98 %					

st_kl

End of report

Printed: 02.11.2021